Topics

AstraZeneca, FibroGen say pooled analyses of HIF-PH inhibitor roxadustat show no increased CV risk in CKD-associated anaemia http://www.firstwordpharma.com/node/1679792?tsid=28®ion_id=6#axzz64iW891AM …

15:31 EST 8 Nov 2019 | FirstWord Pharma

AstraZeneca, FibroGen say pooled analyses of HIF-PH inhibitor roxadustat show no increased CV risk in CKD-associated anaemia http://www.firstwordpharma.com/node/1679792?tsid=28&region_id=6#axzz64iW891AM …

Original Article: AstraZeneca, FibroGen say pooled analyses of HIF-PH inhibitor roxadustat show no increased CV risk in CKD-associated anaemia http://www.firstwordpharma.com/node/1679792?tsid=28®ion_id=6#axzz64iW891AM …

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca, FibroGen say pooled analyses of HIF-PH inhibitor roxadustat show no increased CV risk in CKD-associated anaemia http://www.firstwordpharma.com/node/1679792?tsid=28®ion_id=6#axzz64iW891AM …"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...